Development and validation of systems for rational use of viral load testing in adults receiving first-line ART in sub-Saharan Africa

AIDS

Volumn 25, Issue 13, 2011, Pages 1627-1635

  Abouyannis, Michael ^a   Menten, Joris ^b   Kiragga, Agnes ^c   Lynen, Lutgarde ^b   Robertson, Gavin ^c   Castelnuovo, Barbara ^c   Manabe, Yukari C ^c,d   Reynolds, Steven J ^d,e   Roberts, Lesley ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c Infectious Diseases Institute   (Uganda)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

antiretroviral therapy; HIV; resource constrained settings; treatment failure; Uganda; viral load

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL VOLUME; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG TREATMENT FAILURE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILLNESS TRAJECTORY; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; UGANDAN SCORING SYSTEM; VALIDATION PROCESS; VIRUS CULTURE; VIRUS LOAD;

ADULT; ALGORITHMS; ANTI-RETROVIRAL AGENTS; CAMBODIA; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; UGANDA; VIRAL LOAD; WORLD HEALTH ORGANIZATION;

EID: 80051780681     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328349a414     Document Type: Article

References (48)

1. WHO 2009 - WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report, September 2009. http://www.who.int/hiv/pub/2009progressreport/en/. [Accessed 19 February 2010]
2. Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A. Secondline antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 2008;22:1305-1312.
3. Collini P, Schwab U, Sarfo S, Obeng-Baah J, Norman B, Chadwick D, et al. Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort. Clin Infect Dis 2009;48:988-991.
4. Keiser O. Switching to second line ART, and mortality in resource-limited settings: collaborative analysis of treatment programs in Africa, Asia and Latin America. Presented at 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada.
5. Lynen L, Van Griensven J, Elliott J. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings. Curr Opin HIV AIDS 2010;5:1-5.
6. Harries AD, Zachariah R, van Oosterhout JJ, Reid SD, Hosseinipour MC, Arendt V, et al. Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. Lancet Infect Dis 2010;10:60-65.
7. Gazzard BG, BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1 infected adults with antiretroviral therapy. HIV Med 2008;9:563-608.
8. Hammer SM, Saag MS, Schechter M, Montaner J S G, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843. (Pubitemid 44223106)
9. Fiscus SA, Cheng B, Crowe SM, Dementer L, Jennings C, Miller V, et al. HIV-1 viral load assays for resource limited settings. PLoS Med 2006;3:e417.
10. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007;44:128-134. (Pubitemid 44968997)
11. Schooley RT. Viral load testing in resource-limited settings. Clin Infect Dis 2007;44:139-140. (Pubitemid 44968999)
12. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: recommendations for a public health approach (2006 revision). Geneva: WHO; 2006. http://www.who.int/ hiv/pub/arv/adult/en/index.html. [Accessed 19 February 2010]
13. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: WHO; 2007. www.who.int/hiv/pub/ guidelines/HIV-staging150307.pdf. [Accessed 19 February 2010]
14. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008;22:1971-1977.
15. Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, Hancock J, et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008;49:477-484.
16. Meya D, Spacek LA, Tibenderana H, John L, Namugga I, Magero S, et al. Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria. J Int AIDS Soc 2009;12:3.
17. Keiser O, Macphail P, Boulle A, Wood R, Schechter M, Dabis F, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health 2009;14:1220-1225.
18. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009;23:697-700.
19. Castelnuovo B, Kiragga A, Schaefer P, Kambugu A, Manabe Y. High rate of misclassification of treatment failure based on WHO immunological criteria in resource limited settings in Uganda. AIDS 2009;23:1295-1296.
20. Rawizza H, Chaplin B, Rao T. Comparison of Immunologic and Virologic Failure Criteria in a Large ART Program in Nigeria. Presented at 17th Conference on Retrovirus and opportunistic Infections; 2010; San Francisco, California, USA.
21. Gupta R, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009;9:409-417.
22. Hosseinipour MC, van Oosterhout J J G, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009;23:1127-1134.
23. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RG, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008;22:2097-2106.
24. Colby DJ. Cost-effectiveness of viral load testing for suspected first-line antiretroviral drug therapy failure in Vietnam. Presented at 2009 HIV/AIDS Implementer's meeting; 2009; Windhoek, Namibia.
25. Castelnuovo B, Byakwaga H, Menten J, Schaefer P, Kamya M, Colebunders R. Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome? AIDS 2008;22:269-273.
26. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008;5:e109.
27. Lynen L, An S, Koole O, Thai S, Ros S, De Munter P, et al. An Algorithm to Optimize Viral Load Testing in HIV-Positive Patients With Suspected First-Line Antiretroviral Therapy Failure in Cambodia. J Acquir Immune Defic Syndr 2009;52:40-48.
28. The Infectious Diseases Institute, Mulago Hospital, Makerere University in Kampala, Uganda. http://www.idi.ac.ug/.
29. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach (2003 revision). Geneva: WHO; 2004. www.who.int/hiv/pub/prev-care/en/ arvrevision2003en.pdf. [Accessed 19 February 2010]
30. Uganda Ministry of Health. National antiretroviral treatment and care guidelines for adults and children. Uganda Ministry of Health; 2003. www.aidsuganda.org/pdf/ARV-Clinical-Guidelines-Final-draft.pdf. [Accessed 19 February 2010]
31. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007;46:187-193. (Pubitemid 47482614)
32. Seymour DG, Green M, Vaz FG. Making better decisions: construction of clinical scoring systems by the Spiegelhalter-Knill-Jones approach. BMJ 1990;300:223-226. (Pubitemid 20045526)
33. Spiegelhalter DJ. Statistical methodology for evaluating gastrointestinal symptoms. Clin Gastroenterol 1985;14:489-515. (Pubitemid 16242179)
34. Berkley JA, Ross A, Mwangi I, Osier F H A, Mohammed M, Shebbe M, et al. Prognostic indicators of early and late death in children admitted to district hospital in Kenya: cohort study. BMJ 2003;326:361.
35. Nakanjako D, Kiragga A, Ibrahim F, Castelnuovo B, Kamya MR, Easterbrook PJ. Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on Antiretroviral Therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther 2008;5:23.
36. Kantor R, Diero L, DeLong A, Kamle L, Muyonga S, Mambo F, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009;49:454-462.
37. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. WHO; 2009. http://www.who.int/hiv/pub/arv/ rapid-advice-art.pdf. [Accessed 12 March 2010]
38. Keiser O, Tweya, Boulle A, Braitstein P, Schechter M, Brinkhof M, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009;23:1867-1874.
39. Reynolds S, Sendagire H, Newell K, Castelnuovo B, Kiragga A, Namugga I, et al. VLM reduces the rate of accumulated genotypic resistance to commonly used ART in Uganda. Presented at 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, Massachusetts, USA.
40. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007;44:447-452. (Pubitemid 46147631)
41. Tuboi SH, Brinkhof M W G, Egger M, Stone RA, Braitstein P, Nash D, et al. Discordant responses to potent antiretroviral treatment in previously naïve HIV-1-infected adults initiating treatment in resource-constrained countries. The Antiretroviral Therapy in Low-Income Countries (ART-LINC) Collaboration. J Acquir Immune Defic Syndr 2007;45:52-59. (Pubitemid 46684443)
42. Tuboi SH, Pacheco AG, Harrison LH, Stone RA, May M, Brinkof MW, et al. Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings. J Acquir Immune Defic Syndr 2010;53:70-77.
43. Chang LW, Harris J, Humphreys E. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings. Cochrane Database Syst Rev 2010: CD008494. doi: 10.1002/14651858. CD008494.
44. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008;371:1443-1451. (Pubitemid 351635534)
45. Coutinho A, Mermin J, Ekwaru J, Were W, Bunnell R, Kaharuza F, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: a randomized trial. Presented at 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, Massachusetts, USA.
46. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Traisaithit P, Barbier S, Techapornroong M, et al. PHPT-3: a randomized clinical trial comparing CD4 vs. viral load ART monitoring/switching strategies in Thailand. Presented at 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, Massachusetts, USA.
47. Kouanfack C, Laurent C, Laborde-Balen G, Aghokeng A, Tchatchueng-Mbougua J, Boyer S, et al. HIV viral load, CD4 cell count, and clinical monitoring vs. clinical monitoring alone for ART in rural hospitals in Cameroon: Stratall ANRS 12110/ESTHER Trial, a randomized noninferiority trial. Presented at 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, Massachusetts, USA.
48. Bendavid E, Young SD, Katzenstein DA, Bayoumi A, Sanders GD, Owens DK. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 2008;168:1910-1918.